Medtronic Set to Announce FQ3 Earnings Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy MDT?
Source: seekingalpha
- Earnings Announcement: Medtronic is set to announce its FQ3 earnings results on February 17 before market open, with consensus EPS estimate at $1.33 and revenue estimate at $8.9 billion, highlighting market interest in its performance.
- Performance Exceeding Expectations: Over the past two years, Medtronic has beaten EPS estimates 100% of the time and revenue estimates 88% of the time, indicating the company's consistent performance and profitability in the market.
- Analyst Expectation Adjustments: In the last 90 days, 18 out of 19 analysts have revised their EPS forecasts lower, while revenue estimates saw 15 upward revisions, reflecting a cautious market outlook on future performance.
- Growth Potential: Medtronic noted in its FQ2 2026 earnings call that it doubled its installed base of Affera mapping systems, which is expected to significantly support future revenue growth and margin expansion, showcasing the company's growth potential in the cardiovascular sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDT
Wall Street analysts forecast MDT stock price to rise
20 Analyst Rating
11 Buy
9 Hold
0 Sell
Moderate Buy
Current: 100.880
Low
102.00
Averages
111.76
High
120.00
Current: 100.880
Low
102.00
Averages
111.76
High
120.00
About MDT
Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Medtronic Q3 Earnings Expectations
- Earnings Release Announcement: Medtronic is set to release its Q3 earnings before the market opens on February 17, with analysts forecasting earnings of $1.34 per share, a slight decline from $1.39 in the previous year, indicating a minor weakening in profitability.
- Revenue Expectations: According to Benzinga Pro, the consensus estimate for Medtronic's quarterly revenue is $8.9 billion, up from $8.29 billion last year, suggesting the company maintains a certain growth momentum in revenue.
- Analyst Rating Upgrade: Needham analyst Mike Matson upgraded Medtronic from Hold to Buy, setting a price target of $121, reflecting a positive outlook on the company's future performance in the market.
- Dividend Yield Analysis: Medtronic currently offers an annual dividend yield of 2.82%, with a quarterly dividend of 71 cents per share; investors aiming for $500 monthly in dividends would need to invest approximately $213,159, highlighting the attractiveness of the company's dividend policy to investors.
See More
Medtronic Set to Announce FQ3 Earnings Results
- Earnings Announcement: Medtronic is set to announce its FQ3 earnings results on February 17 before market open, with consensus EPS estimate at $1.33 and revenue estimate at $8.9 billion, highlighting market interest in its performance.
- Performance Exceeding Expectations: Over the past two years, Medtronic has beaten EPS estimates 100% of the time and revenue estimates 88% of the time, indicating the company's consistent performance and profitability in the market.
- Analyst Expectation Adjustments: In the last 90 days, 18 out of 19 analysts have revised their EPS forecasts lower, while revenue estimates saw 15 upward revisions, reflecting a cautious market outlook on future performance.
- Growth Potential: Medtronic noted in its FQ2 2026 earnings call that it doubled its installed base of Affera mapping systems, which is expected to significantly support future revenue growth and margin expansion, showcasing the company's growth potential in the cardiovascular sector.
See More
Medtronic Launches Stealth AXiS™ Surgical System for Spine Surgery
- FDA Clearance: Medtronic's Stealth AXiS™ surgical system has received FDA clearance, integrating planning, navigation, and robotics to enhance efficiency and precision in spine surgery, which is expected to significantly improve surgical experiences and patient outcomes.
- Real-Time Tracking Innovation: The system's LiveAlign™ segmental tracking feature provides surgeons with real-time visualization of anatomical motion, reducing reliance on repeated imaging and thereby enhancing the consistency of surgical plan execution while minimizing workflow disruptions.
- Smart Ecosystem Integration: As a cornerstone of Medtronic's AiBLE™ smart ecosystem, the Stealth AXiS™ system streamlines surgical workflows by natively integrating planning, navigation, and execution, facilitating information exchange before, during, and after surgery, thus improving overall surgical efficiency.
- Future Expansion Potential: The system is designed not only to meet current spine surgery needs but also to lay the groundwork for future cranial and ENT applications, showcasing Medtronic's ongoing innovation capabilities and market leadership in surgical technology.
See More
FDA Approves Medtronic's Stealth AXiS Surgical System for Spine Procedures
- Real-Time Tracking Technology: Medtronic's Stealth AXiS surgical system has received FDA clearance, featuring the industry-first LiveAlign segmental tracking technology that allows surgeons to visualize anatomical motion and surgical adjustments in real time, thereby reducing reliance on repeated imaging and enhancing surgical efficiency.
- Surgical Workflow Optimization: The system streamlines information exchange before, during, and after spine surgery, significantly lowering the risk of manual steps and workflow disruptions, ensuring that surgeons can execute patient-specific surgical plans more consistently.
- Market Competitive Advantage: With the innovative capabilities of Stealth AXiS, Medtronic further solidifies its leadership position in the spine surgery equipment market, which is expected to attract more healthcare institutions to adopt the system, driving future revenue growth for the company.
- Strategic Collaboration Potential: Medtronic's technological advancements in spine surgery complement its collaborations in emerging fields like brain-computer interfaces, indicating the company's commitment to enhancing overall healthcare service quality and market competitiveness through innovation.
See More
Medtronic Launches Next-Gen Spine Surgery Robotics System
- FDA Clearance: Medtronic's Stealth AXiS surgical system has received FDA clearance, becoming the first integrated robotics platform that combines planning, navigation, and robotics for spine surgery, marking a significant innovation in healthcare technology.
- Modular Design Benefits: The system features a modular robotic design that allows healthcare institutions to deploy according to current needs while supporting future expansions, enhancing adaptability across various surgical procedures and specialties.
- Real-Time Tracking Innovation: The LiveAlign segmental tracking capability of the Stealth AXiS system enables surgeons to visualize anatomical motion and patient alignment in real time, reducing reliance on repeated imaging and improving the consistency and efficiency of surgical execution.
- Integration into Smart Ecosystem: As a cornerstone of Medtronic's AiBLE smart ecosystem, the Stealth AXiS system facilitates a seamless flow of information across the surgical continuum, enhancing collaboration and information sharing during surgical procedures, thus driving the advancement of intelligent healthcare services.
See More
Medtronic Launches Stealth AXiS™ Surgical System for Spine Surgery
- FDA Clearance: Medtronic's Stealth AXiS™ surgical system has received FDA clearance, marking a significant technological innovation in spine surgery that is expected to enhance surgical efficiency and safety in hospitals and ambulatory surgery centers.
- Real-Time Visualization Technology: The system's LiveAlign™ segmental tracking feature provides surgeons with real-time visualization of anatomical motion, reducing reliance on repeated imaging and improving the consistency of surgical plan execution, thereby lowering surgical risks.
- Smart Ecosystem Integration: As a cornerstone of Medtronic's AiBLE™ smart ecosystem, the Stealth AXiS™ system integrates planning, navigation, and execution, aiming to streamline surgical workflows and enhance the flow of information, improving data exchange capabilities before and after surgery.
- Future Expansion Potential: The system is designed not only for spine surgery but also lays the groundwork for future cranial and ENT applications, showcasing Medtronic's long-term strategic positioning and commitment to continuous innovation in healthcare technology.
See More
Medtronic Q3 Earnings Expectations
- Earnings Release Announcement: Medtronic is set to release its Q3 earnings before the market opens on February 17, with analysts forecasting earnings of $1.34 per share, a slight decline from $1.39 in the previous year, indicating a minor weakening in profitability.
- Revenue Expectations: According to Benzinga Pro, the consensus estimate for Medtronic's quarterly revenue is $8.9 billion, up from $8.29 billion last year, suggesting the company maintains a certain growth momentum in revenue.
- Analyst Rating Upgrade: Needham analyst Mike Matson upgraded Medtronic from Hold to Buy, setting a price target of $121, reflecting a positive outlook on the company's future performance in the market.
- Dividend Yield Analysis: Medtronic currently offers an annual dividend yield of 2.82%, with a quarterly dividend of 71 cents per share; investors aiming for $500 monthly in dividends would need to invest approximately $213,159, highlighting the attractiveness of the company's dividend policy to investors.
See More
Medtronic Set to Announce FQ3 Earnings Results
- Earnings Announcement: Medtronic is set to announce its FQ3 earnings results on February 17 before market open, with consensus EPS estimate at $1.33 and revenue estimate at $8.9 billion, highlighting market interest in its performance.
- Performance Exceeding Expectations: Over the past two years, Medtronic has beaten EPS estimates 100% of the time and revenue estimates 88% of the time, indicating the company's consistent performance and profitability in the market.
- Analyst Expectation Adjustments: In the last 90 days, 18 out of 19 analysts have revised their EPS forecasts lower, while revenue estimates saw 15 upward revisions, reflecting a cautious market outlook on future performance.
- Growth Potential: Medtronic noted in its FQ2 2026 earnings call that it doubled its installed base of Affera mapping systems, which is expected to significantly support future revenue growth and margin expansion, showcasing the company's growth potential in the cardiovascular sector.
See More
Medtronic Launches Stealth AXiS™ Surgical System for Spine Surgery
- FDA Clearance: Medtronic's Stealth AXiS™ surgical system has received FDA clearance, integrating planning, navigation, and robotics to enhance efficiency and precision in spine surgery, which is expected to significantly improve surgical experiences and patient outcomes.
- Real-Time Tracking Innovation: The system's LiveAlign™ segmental tracking feature provides surgeons with real-time visualization of anatomical motion, reducing reliance on repeated imaging and thereby enhancing the consistency of surgical plan execution while minimizing workflow disruptions.
- Smart Ecosystem Integration: As a cornerstone of Medtronic's AiBLE™ smart ecosystem, the Stealth AXiS™ system streamlines surgical workflows by natively integrating planning, navigation, and execution, facilitating information exchange before, during, and after surgery, thus improving overall surgical efficiency.
- Future Expansion Potential: The system is designed not only to meet current spine surgery needs but also to lay the groundwork for future cranial and ENT applications, showcasing Medtronic's ongoing innovation capabilities and market leadership in surgical technology.
See More
FDA Approves Medtronic's Stealth AXiS Surgical System for Spine Procedures
- Real-Time Tracking Technology: Medtronic's Stealth AXiS surgical system has received FDA clearance, featuring the industry-first LiveAlign segmental tracking technology that allows surgeons to visualize anatomical motion and surgical adjustments in real time, thereby reducing reliance on repeated imaging and enhancing surgical efficiency.
- Surgical Workflow Optimization: The system streamlines information exchange before, during, and after spine surgery, significantly lowering the risk of manual steps and workflow disruptions, ensuring that surgeons can execute patient-specific surgical plans more consistently.
- Market Competitive Advantage: With the innovative capabilities of Stealth AXiS, Medtronic further solidifies its leadership position in the spine surgery equipment market, which is expected to attract more healthcare institutions to adopt the system, driving future revenue growth for the company.
- Strategic Collaboration Potential: Medtronic's technological advancements in spine surgery complement its collaborations in emerging fields like brain-computer interfaces, indicating the company's commitment to enhancing overall healthcare service quality and market competitiveness through innovation.
See More
Medtronic Launches Next-Gen Spine Surgery Robotics System
- FDA Clearance: Medtronic's Stealth AXiS surgical system has received FDA clearance, becoming the first integrated robotics platform that combines planning, navigation, and robotics for spine surgery, marking a significant innovation in healthcare technology.
- Modular Design Benefits: The system features a modular robotic design that allows healthcare institutions to deploy according to current needs while supporting future expansions, enhancing adaptability across various surgical procedures and specialties.
- Real-Time Tracking Innovation: The LiveAlign segmental tracking capability of the Stealth AXiS system enables surgeons to visualize anatomical motion and patient alignment in real time, reducing reliance on repeated imaging and improving the consistency and efficiency of surgical execution.
- Integration into Smart Ecosystem: As a cornerstone of Medtronic's AiBLE smart ecosystem, the Stealth AXiS system facilitates a seamless flow of information across the surgical continuum, enhancing collaboration and information sharing during surgical procedures, thus driving the advancement of intelligent healthcare services.
See More
Medtronic Launches Stealth AXiS™ Surgical System for Spine Surgery
- FDA Clearance: Medtronic's Stealth AXiS™ surgical system has received FDA clearance, marking a significant technological innovation in spine surgery that is expected to enhance surgical efficiency and safety in hospitals and ambulatory surgery centers.
- Real-Time Visualization Technology: The system's LiveAlign™ segmental tracking feature provides surgeons with real-time visualization of anatomical motion, reducing reliance on repeated imaging and improving the consistency of surgical plan execution, thereby lowering surgical risks.
- Smart Ecosystem Integration: As a cornerstone of Medtronic's AiBLE™ smart ecosystem, the Stealth AXiS™ system integrates planning, navigation, and execution, aiming to streamline surgical workflows and enhance the flow of information, improving data exchange capabilities before and after surgery.
- Future Expansion Potential: The system is designed not only for spine surgery but also lays the groundwork for future cranial and ENT applications, showcasing Medtronic's long-term strategic positioning and commitment to continuous innovation in healthcare technology.
See More
